PMID: 8596376Mar 9, 1996Paper

Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393

Lancet
B I ErikssonP Close

Abstract

The frequency of thromboembolism after major orthopaedic surgery continues to be high despite prophylaxis. New agents such as CGP 39393, a recombinant form of hirudin, may be more effective than existing therapies. In this double-blind, multicentre, European study the efficacy of three doses of CGP 39393, in comparison with unfractionated heparin, were examined in 1119 patients undergoing elective hip surgery. Patients were randomly allocated to receive by subcutaneous injection either 10, 15, or 20 mg of CGP 39393 twice daily or 5000 IU of heparin three times daily. All treatments were started just before surgery and continued for 8-11 days, until bilateral venography was performed. The occurrence of thromboembolism was significantly reduced in patients treated with CGP 39393 compared to heparin. The frequency of deep-vein thrombosis was 34.2% in the heparin group as compared to 23.9% (p=0.0113), 18.4% (p=0.0003), and 17.7% (p=0.0001) in the 10 mg, 15 mg, and 20 mg CGP 39393 groups, respectively. At all dose levels, CGP 39393 was more effective than heparin in preventing proximal deep-vein thrombosis. The frequency of proximal thrombosis was 19.6% in the heparin group as compared to 8.5% (p<0.001), 3.1% (p<0.001), and 2.4% (p<...Continue Reading

References

Dec 1, 1979·AJR. American Journal of Roentgenology·D R BielloB A Siegel
Feb 1, 1972·Archives of Surgery·K Rabinov, S Paulin
Apr 1, 1981·Annals of Internal Medicine·K M Moser, J R LeMoine

❮ Previous
Next ❯

Citations

Aug 23, 2001·Thrombosis Research·A Y Lee
Jun 24, 2003·Thrombosis Research·Bengt I Eriksson
Feb 11, 2000·Thrombosis Research·G Agnelli, F Sonaglia
Jun 7, 2002·Lancet·Michael Rud LassenUNKNOWN European Pentasaccharide Elective Surgery Study (EPHESUS) Steering Committee
Aug 26, 1998·International Journal of Cardiology·G Agnelli, F Sonaglia
Aug 19, 1999·Critical Reviews in Oncology/hematology·G Agnelli, F Sonaglia
Nov 24, 1999·Kidney International. Supplement·R D FrankH P Kierdorf
Nov 14, 1997·The New England Journal of Medicine·B M Ewenstein
Mar 28, 1998·The New England Journal of Medicine·M W Ketterer
Jan 17, 2002·The New England Journal of Medicine·K A BauerUNKNOWN Steering Committee of the Pentasaccharide in Major Knee Surgery Study
Jan 17, 2002·The New England Journal of Medicine·B I ErikssonUNKNOWN Steering Committee of the Pentasaccharide in Hip-Fracture Surgery Study
Sep 1, 1999·Current Opinion in Hematology·G F Pineo, R D Hull
Dec 9, 2004·Journal of Infusion Nursing : the Official Publication of the Infusion Nurses Society·Howard C Cook
Oct 15, 2005·BMJ : British Medical Journal·Roberta JoppiSilvio Garattini
Apr 7, 2005·Pathophysiology of Haemostasis and Thrombosis·Bengt Eriksson
Jul 13, 2004·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Karl-Georg Fischer
Jan 20, 2004·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Jeffrey I Weitz, Mark A Crowther
Jun 1, 1996·Lancet·D J Williams, A Mahomed
Aug 12, 1999·British Journal of Haematology·G HuhleJ Harenberg
Jun 19, 2004·International Anesthesiology Clinics·Mark E Comunale, Elizabeth M Van Cott
Oct 5, 2010·European Journal of Anaesthesiology·Wiebke GogartenUNKNOWN European Scoeity of Anaesthesiology
Nov 17, 2009·Journal of Clinical Pharmacology·Anne N Nafziger, Joseph S Bertino
Apr 15, 2006·Cardiovascular Drug Reviews·Shaker A Mousa, Hikmat N Abdel-Razeq
Jul 5, 2005·Expert Opinion on Investigational Drugs·B KaiserJ Fareed
Apr 27, 2001·Expert Opinion on Investigational Drugs·C D Nicholson, A W Lensing
Nov 4, 2000·Expert Opinion on Investigational Drugs·M ErikssonA Nordgren
Jul 5, 2005·Expert Opinion on Investigational Drugs·W JeskeJ Fareed
Jul 2, 2005·Expert Opinion on Emerging Drugs·O IqbalJ Fareed
Jul 2, 2005·Expert Opinion on Emerging Drugs·Omer IqbalWilliam Wehrmacher

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.